Form 4: NewAmsterdam Pharma CAO Exercises, Sells Shares

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, exercised stock options and subsequently sold a significant portion of the acquired shares.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reported transactions on September 9, 2025.
• Exercised options to acquire 150,000 Ordinary Shares at an exercise price of $10.00 per share.
• Subsequently sold 53,104 Ordinary Shares at a weighted average price of $25.31 per share, with transactions ranging from $24.87 to $25.86.
• Further sold 96,896 Ordinary Shares at a weighted average price of $26.11 per share, with transactions ranging from $25.87 to $26.28.
• Following these transactions, Kooij beneficially owns 15,000 Ordinary Shares directly.
• Kooij also beneficially owns 280,015 derivative securities (options) after the reported transactions.

Sentiment

Score: 6

Explanation: The exercise of options at a lower price and subsequent sale at a higher price is a positive personal financial event for the insider. While the sale of all acquired shares might be viewed with slight caution, it is a common practice for liquidity or tax purposes and does not inherently reflect negatively on the company's future prospects based solely on this filing.

Positives

• The Chief Accounting Officer exercised options, indicating a prior belief in the company's value.
• Shares were sold at a significant premium to the exercise price ($25.31 and $26.11 average sale prices vs. $10.00 exercise price), representing a substantial personal financial gain for the insider.

Negatives

• The Chief Accounting Officer sold a total of 150,000 Ordinary Shares, representing all shares acquired through the option exercise, which could be interpreted as a lack of conviction in the stock's immediate future by some investors, despite being a common practice for liquidity or tax planning.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Industry Context

This transaction is an individual insider trading report and does not provide information to analyze broader industry trends or competitors.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a key executive differently; some may view it as a routine personal financial decision, while others might perceive it as a signal regarding the company's short-term prospects.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, insider trading, stock options, share sale, executive compensation, Form 4, Chief Accounting Officer